Immunovant Inc (IMVT)

$25.10 +0.10 (0.40%)
Market Cap 4.97B
Revenue (ttm) 0.00
Net Income (ttm) -413.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,109,800
Avg Vol 1,370,958
Day's Range N/A - N/A
Shares Out 203.53M
Stochastic %K 24%
Beta 0.62
Analysts Strong Sell
Price Target $41.12

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 580 3099
Address:
320 West 37th Street, 6th Floor, New York, United States
mickeyp_
mickeyp_ Mar. 18 at 3:24 PM
$IMVT breaking down ...
0 · Reply
TradeTracs
TradeTracs Mar. 9 at 5:45 AM
My two health tech base names $ABBV & $IMVT still grinding sideways in their respective bases. have to be patient and let this play out. IMVT 10 ema weekly support
1 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 6:41 PM
$IMVT up 17% in just 3 months — and the real catalyst may still be ahead 🚀 IMVT-1402 is advancing across multiple autoimmune trials, with several data readouts expected in 2026–2027. The company also holds $994.5M in cash to support development — a sizable runway for the pipeline. What’s really driving the momentum here? Find out 👉 https://www.zacks.com/stock/news/2879653/immunovant-stock-surges-17-in-3-months-whats-driving-it?cid=sm-stocktwits-2-2879653-teaser-36213&ADID=SYND_STOCKTWITS_TWEET_2_2879653_TEASER_36213
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 5:41 PM
$IMVT surges 17% in the past three months — what's fueling the rally? 🚀 The boost comes from positive investor confidence driven by IMVT-1402's progress in autoimmune indications and a solid cash position with $994.5M on hand. Key data from trials expected in 2026-2027. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2879653/immunovant-stock-surges-17-in-3-months-whats-driving-it?cid=sm-stocktwits-2-2879653-body-36209&ADID=SYND_STOCKTWITS_TWEET_2_2879653_BODY_36209
0 · Reply
History101
History101 Feb. 27 at 9:30 PM
$IMVT CNBC's Carter Worth is bullish on IMVT: https://www.cnbc.com/2026/02/27/theres-a-bearish-to-bullish-reversal-happening-in-this-mid-cap-biotech-stock-says-carter-worth-.html
0 · Reply
TradeTracs
TradeTracs Feb. 26 at 9:07 PM
Some new prospects that fit the bill. $NEM, $HL, $FLEX, $IMVT are very similar & some also share the same sector (clues to look for). How did i find these two and all four of the above mentioned names before they blasted off? 🚀 Using @TradeTracs scanners and prebuilt tools/features🥱 Unmatched efficiency. The toolbox to end all needless subs/time wasting practices that don't serve your gains Keep up to date with a follow, and stay on the lookout for the unveiling to come 🙌
0 · Reply
Quantumup
Quantumup Feb. 26 at 4:07 PM
Evercore ISI reiterated $VRDN Outperform-$45 and added to its TAP Outperform List. $AMGN $IMVT - ROIV $ALMS NVS $TRML Jefferies⬆️the PT to $45 from $44 and reiterated at a Buy rating. Here's what Evercore ISI and Jefferies had to say: https://x.com/Quantumup1/status/2027052196878041525?s=20
0 · Reply
TradeTracs
TradeTracs Feb. 24 at 10:14 PM
$IMVT solid horizontal base continuation through last earnings. 27.50-28 trigger
0 · Reply
StockConsultant
StockConsultant Feb. 24 at 2:22 PM
$IMVT Immunovant stock, watch for a top of range breakout, mulitple attempts at https://stockconsultant.com/?IMVT
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 10:59 AM
$IMVT RSI: 53.36, MACD: 0.1493 Vol: 0.73, MA20: 26.17, MA50: 26.06 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on IMVT
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Feb 6, 2026, 1:24 PM EST - 5 weeks ago

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Feb 6, 2026, 7:00 AM EST - 5 weeks ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Jan 23, 2026, 5:25 PM EST - 7 weeks ago

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement

Dec 12, 2025, 4:28 PM EST - 3 months ago

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement

Immunovant Announces Pricing of $550 Million Common Stock Financing

Dec 11, 2025, 1:29 AM EST - 3 months ago

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 12:31 PM EST - 4 months ago

Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Nov 10, 2025, 7:00 AM EST - 4 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Oct 27, 2025, 4:10 PM EDT - 5 months ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

ROIV

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Sep 3, 2025, 12:57 PM EDT - 6 months ago

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

Aug 27, 2025, 8:33 PM EDT - 7 months ago

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Aug 11, 2025, 7:00 AM EDT - 7 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

May 29, 2025, 7:00 AM EDT - 10 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward

Mar 19, 2025, 5:07 PM EDT - 1 year ago

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Mar 19, 2025, 7:59 AM EDT - 1 year ago

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 19, 2025, 7:45 AM EDT - 1 year ago

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 18, 2025, 4:32 PM EDT - 1 year ago

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Feb 6, 2025, 6:30 AM EST - 1 year ago

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Jan 24, 2025, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Dec 27, 2024, 10:50 AM EST - 1 year ago

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial

Dec 11, 2024, 6:25 AM EST - 1 year ago

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Top 2 Health Care Stocks That May Collapse This Quarter

Sep 9, 2024, 9:12 AM EDT - 1 year ago

Top 2 Health Care Stocks That May Collapse This Quarter

TERN

Immunovant Provides Update on Graves' Disease Development Program

Sep 9, 2024, 3:55 AM EDT - 1 year ago

Immunovant Provides Update on Graves' Disease Development Program

Immunovant to Host Graves' Disease Program Update on September 9, 2024

Sep 5, 2024, 6:30 AM EDT - 1 year ago

Immunovant to Host Graves' Disease Program Update on September 9, 2024

Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging

Aug 6, 2024, 8:25 AM EDT - 1 year ago

Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging

FIP FTAI OABI PRPL REAL RICK

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

May 29, 2024, 4:01 PM EDT - 1 year ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 4, 2024, 2:12 AM EDT - 2 years ago

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Immunovant Awarded U.S. Patent for IMVT-1402

Mar 12, 2024, 7:30 AM EDT - 2 years ago

Immunovant Awarded U.S. Patent for IMVT-1402

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Feb 12, 2024, 7:00 AM EST - 2 years ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas

Jan 9, 2024, 9:00 AM EST - 2 years ago

Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas

BUR LQDA

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Dec 20, 2023, 4:30 PM EST - 2 years ago

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Best Small-Cap Stocks to Buy for 2024 and Beyond

Dec 14, 2023, 1:24 PM EST - 2 years ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH PRVA RCKT

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Nov 28, 2023, 7:00 AM EST - 2 years ago

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena

Nov 14, 2023, 3:48 AM EST - 2 years ago

Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena

Immunovant to Present at Upcoming Investor Conferences

Nov 13, 2023, 8:00 AM EST - 2 years ago

Immunovant to Present at Upcoming Investor Conferences

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 2, 2023, 4:52 PM EDT - 2 years ago

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunovant Announces Pricing of $450 Million Common Stock Financing

Sep 27, 2023, 11:41 PM EDT - 2 years ago

Immunovant Announces Pricing of $450 Million Common Stock Financing

Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock

Sep 27, 2023, 5:30 AM EDT - 2 years ago

Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Sep 26, 2023, 5:00 PM EDT - 2 years ago

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

Sep 26, 2023, 4:20 PM EDT - 2 years ago

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)

Sep 26, 2023, 11:10 AM EDT - 2 years ago

Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)

Immunovant shares surge after antibody treatment succeeds in early-stage study

Sep 26, 2023, 7:57 AM EDT - 2 years ago

Immunovant shares surge after antibody treatment succeeds in early-stage study

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Sep 26, 2023, 6:00 AM EDT - 2 years ago

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

Sep 25, 2023, 11:01 PM EDT - 2 years ago

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

mickeyp_
mickeyp_ Mar. 18 at 3:24 PM
$IMVT breaking down ...
0 · Reply
TradeTracs
TradeTracs Mar. 9 at 5:45 AM
My two health tech base names $ABBV & $IMVT still grinding sideways in their respective bases. have to be patient and let this play out. IMVT 10 ema weekly support
1 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 6:41 PM
$IMVT up 17% in just 3 months — and the real catalyst may still be ahead 🚀 IMVT-1402 is advancing across multiple autoimmune trials, with several data readouts expected in 2026–2027. The company also holds $994.5M in cash to support development — a sizable runway for the pipeline. What’s really driving the momentum here? Find out 👉 https://www.zacks.com/stock/news/2879653/immunovant-stock-surges-17-in-3-months-whats-driving-it?cid=sm-stocktwits-2-2879653-teaser-36213&ADID=SYND_STOCKTWITS_TWEET_2_2879653_TEASER_36213
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 5:41 PM
$IMVT surges 17% in the past three months — what's fueling the rally? 🚀 The boost comes from positive investor confidence driven by IMVT-1402's progress in autoimmune indications and a solid cash position with $994.5M on hand. Key data from trials expected in 2026-2027. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2879653/immunovant-stock-surges-17-in-3-months-whats-driving-it?cid=sm-stocktwits-2-2879653-body-36209&ADID=SYND_STOCKTWITS_TWEET_2_2879653_BODY_36209
0 · Reply
History101
History101 Feb. 27 at 9:30 PM
$IMVT CNBC's Carter Worth is bullish on IMVT: https://www.cnbc.com/2026/02/27/theres-a-bearish-to-bullish-reversal-happening-in-this-mid-cap-biotech-stock-says-carter-worth-.html
0 · Reply
TradeTracs
TradeTracs Feb. 26 at 9:07 PM
Some new prospects that fit the bill. $NEM, $HL, $FLEX, $IMVT are very similar & some also share the same sector (clues to look for). How did i find these two and all four of the above mentioned names before they blasted off? 🚀 Using @TradeTracs scanners and prebuilt tools/features🥱 Unmatched efficiency. The toolbox to end all needless subs/time wasting practices that don't serve your gains Keep up to date with a follow, and stay on the lookout for the unveiling to come 🙌
0 · Reply
Quantumup
Quantumup Feb. 26 at 4:07 PM
Evercore ISI reiterated $VRDN Outperform-$45 and added to its TAP Outperform List. $AMGN $IMVT - ROIV $ALMS NVS $TRML Jefferies⬆️the PT to $45 from $44 and reiterated at a Buy rating. Here's what Evercore ISI and Jefferies had to say: https://x.com/Quantumup1/status/2027052196878041525?s=20
0 · Reply
TradeTracs
TradeTracs Feb. 24 at 10:14 PM
$IMVT solid horizontal base continuation through last earnings. 27.50-28 trigger
0 · Reply
StockConsultant
StockConsultant Feb. 24 at 2:22 PM
$IMVT Immunovant stock, watch for a top of range breakout, mulitple attempts at https://stockconsultant.com/?IMVT
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 10:59 AM
$IMVT RSI: 53.36, MACD: 0.1493 Vol: 0.73, MA20: 26.17, MA50: 26.06 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TheCentWise
TheCentWise Feb. 19 at 8:39 AM
$IMVT Immunova to Acquire AlphaTON Subsidiary Iox Therapeutics Immunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a strategic pivot for a crypto-focused treasury firm as markets swing in 2026. https://thecentwise.com/cryptocurrency/immunova-to-acquire-alphaton-subsidiary-iox-therapeutics
0 · Reply
Quantumup
Quantumup Feb. 18 at 1:28 PM
Truist reiterated $VRDN Buy-$40 and said, REVEAL-1 Topline Preview: Ele' Positioned to Hit Proptosis Bar, after its KOLs check. $AMGN $IMVT - ROIV NVS $ALMS $TRML Truist additionally said, Ahead of VRDN's REVEAL-1 topline for elegrobart (Ele', fka VRDN-003 SC), a half-life extended, SC, IGF-1Ra for active TED, we checked in with KOLs for updated views on Ele' and the broader story. While management targets a 50-70% placebo-adjusted proptosis responder rate, physicians would accept the low end given the strong convenience advantage. Ele' is seen as a potential "game-changer" particularly in chronic and low-CAS patients. A REVEAL-1 win would meaningfully de-risk REVEAL-2 in 2Q and support our ~ $1.3B peak revenue est. Our check-in on volatility surface and the options book for VRDN aligns with our positive views, NT and LT. Reiterate Buy, $40 PT.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 11 at 2:12 PM
$IMVT Share Price: $26.68 Contract Selected: May 15, 2026 $25 Calls Buy Zone: $3.21 – $3.97 Target Zone: $5.84 – $7.14 Potential Upside: 72% ROI Time to Expiration: 92 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Alfalcon
Alfalcon Feb. 9 at 11:23 PM
$ROIV our dove finally outpaced $IMVT
0 · Reply
ZacksResearch
ZacksResearch Feb. 9 at 6:48 PM
$IMVT just surprised the Street — and the pipeline is front and center 👀 Immunovant posted a narrower-than-expected Q3 loss, raised $550M to fund IMVT-1402 through launch, and is advancing multiple studies with key data ahead — plenty for investors to digest. Full pipeline and funding breakdown here 👉 https://www.zacks.com/stock/news/2841900/imvt-posts-narrower-than-expected-q3-loss-pipeline-in-focus?cid=sm-stocktwits-2-2841900-teaser-32666&ADID=SYND_STOCKTWITS_TWEET_2_2841900_TEASER_32666
0 · Reply
ZacksResearch
ZacksResearch Feb. 9 at 5:48 PM
$IMVT narrows Q3 loss but no revenue yet — what’s driving the stock? 🤔 📈 Shares surged 38.6% over the past year, beating the industry’s 20.3% growth. 🤑 Raised $550M in December 2025 to fund IMVT-1402’s potential commercial launch. Discover the full story behind IMVT’s pipeline and financials here 👉 https://www.zacks.com/stock/news/2841900/imvt-posts-narrower-than-expected-q3-loss-pipeline-in-focus?cid=sm-stocktwits-2-2841900-body-32665&ADID=SYND_STOCKTWITS_TWEET_2_2841900_BODY_32665
0 · Reply
ortega1963
ortega1963 Feb. 9 at 9:03 AM
$IMVT Spread your Wings and fly away
0 · Reply
NasdaqKnight
NasdaqKnight Feb. 7 at 3:33 PM
🚨 $IMVT Update | PT $50 Lifesciences company stays laser-focused on execution across multiple late-stage programs. Key catalysts coming in 2026: If this is helpful to you, tap @NasdaqKnight • TED data expected H1 2026 • RA & CLE data expected H2 2026 Investors should watch these readouts—they could be major drivers for $IMVT shares as the pipeline progresses. Multiple late-stage shots on goal make 2026 a potentially high-action year.
0 · Reply
d_risk
d_risk Feb. 6 at 6:37 PM
$IMVT - Immunovant Inc. Common Stock - 10Q - Updated Risk Factors IMVT flags rising R&D and trial cost/timing risk, tighter exposure to material breaches in key licensing that could trigger damages or loss of IP rights, and new uncertainty around whether its cross-border tax structure will deliver intended benefits. #Biotechnology #TaxUncertainty #IntellectualProperty #LicensingRisk #R&DRisk 🟢 Added 🟠 Removed https://d-risk.ai/IMVT/10-Q/2026-02-06
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Feb. 6 at 4:26 PM
$IMVT the table is set
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 6 at 2:03 PM
$IMVT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.61 up 19.74% YoY • Immunovant expects its $994.5 million cash and cash equivalents as of December 31, 2025, to fund operating expenses and capital requirements for announced indications through the potential commercial launch of IMVT-1402 in GD.
0 · Reply
theoptionsplug
theoptionsplug Feb. 6 at 4:00 AM
THINGS TO WATCH, FRIDAY, 2/6/26 👁️ $TM $CNC $IMVT $MSTR $COIN
0 · Reply